Transcriptome-wide profiling of patient-derived melanoma samples has led to the identification of specific signatures associated with major oncogene subtypes (e.g., BRAF-mutant, NRAS-mutant, NF1-mutant, and triple wild-type) and prognoses [3–5]. The gene discussed is NF1; the disease is melanoma.